Markus Thiemann

High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90

G. Schellong, Richard Pötter, Jürgen Brämswig et al. · Journal of Clinical Oncology · 1999 · 250 citations

Medicine, Oncology, Pediatrics +15

Production of different phenotypes from the same genotype in the same environment by developmental variation

Günter Vogt, Martin Huber, Markus Thiemann et al. · Journal of Experimental Biology · 2008 · 225 citations

Life Sciences, Biology, Developmental Biology +17

Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition

Claudia Blattmann, Susanne Oertel, Volker Ehemann et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 93 citations

Medicine, Cancer Biology, Oncology +16

Establishment of a patient-derived orthotopic osteosarcoma mouse model

Claudia Blattmann, Markus Thiemann, Albrecht Stenzinger et al. · Journal of Translational Medicine · 2015 · 49 citations · Full text

Medicine, Cancer Biology, Oncology +15

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model

Markus Thiemann, Susanne Oertel, Volker Ehemann et al. · Radiation Oncology · 2012 · 31 citations · Full text

Medicine, Oncology, Pharmacology +13